Search clinical trials for: Anti-PD-1/PD-L1 monoclonal antibody

Total 2322 results

National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Hematopoietic and Lymphoid System Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Menarini International Operations Luxembourg SA

Completed

Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout (FORWARD)

Gout

Poland, Serbia, Germany, Italy, Netherlands, Romania
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

Carcinoma, Non-Small-Cell Lung | Lung Adenocarcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern Denmark
SignaTope GmbH, Germany

Completed

Flucloxacillin as an Inducer of CYP-enzymes

Healthy Volunteers | Drug Drug Interaction

Denmark
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
University of Illinois at Chicago
HiberCell, Inc.

Terminated

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer (PM-01)

Pancreatic Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Advanced Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Completed

Bevacizumab in Multiple Phase I Combinations

Advanced Cancer

United States
GRADE Study Group
Bristol-Myers Squibb; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (GRADE)

Type 2 Diabetes | Comparative Effectiveness of Glycemia-lowering Medications

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Recurrent Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Lung Squamous Cell Carcinoma
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
AstraZeneca

Completed

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Multiple Myeloma

United States, Netherlands, Sweden, Denmark
National Cancer Institute (NCI)

Active, not recruiting

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Metastatic Merkel Cell Carcinoma | Metastatic Skin... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
M.D. Anderson Cancer Center

Terminated

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous... and other conditions

United States, Puerto Rico, South Africa
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Canada, Ireland, Peru, South Africa
National Cancer Institute (NCI)

Active, not recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
Uma Borate

Suspended

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Breast Cancer | Ovarian Cancer

United States
Roswell Park Cancer Institute
Pfizer

Active, not recruiting

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Washington University School of Medicine

Terminated

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
University of Chicago
National Cancer Institute (NCI)

Terminated

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

United States
James J. Peters Veterans Affairs Medical Center

Unknown

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

Gastro Esophageal Reflux Disorder

United States
M.D. Anderson Cancer Center

Completed

HAI Abraxane With Gemcitabine and Bevacizumab

Advanced Cancers

United States
MEDSI Clinical Hospital 1, ICU

Recruiting

Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria

Respiratory Tract Infections | Pneumonia | Sepsis | Critical Illness | Respiratory Distress Syndrome | Pneumonia, Ventilator-Associated | Bloodstream Infection

Russian Federation
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
University of Washington

Completed

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Metastatic Malignant Neoplasm in the Bone | Salivary Gland Carcinoma | Metastatic Malignant Neoplasm in the Lung | Stage IV Major Salivary Gland Cancer AJCC v8 | Stage IVA Major Salivary Gland Cancer AJCC v8 | Stage IVB Major Salivary Gland Cancer AJCC v8 | Stage IVC Major Salivary Gland Cancer...

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Withdrawn

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Cervical Carcinoma | Recurrent Melanoma | Vaginal Carcinoma | Esophageal Carcinoma | Mucosal Melanoma | Mucosal Melanoma of the Head and Neck | Oral Cavity Mucosal Melanoma | Stage II Vulvar Cancer AJCC v7 | Stage III Vulvar Cancer AJCC v7 | Stage IIIA Vulvar Cancer AJCC v7 | Stage IIIB Vulvar Cancer AJCC v7 and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Sporadic Papillary Renal Cell Carcinoma

United States

Search clinical trials for: Anti-PD-1/PD-L1 monoclonal antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations